Scrip's 1999 Yearbook is an invaluable addition to your personal, company or business library. It is a one-stop source of facts, data and statistics on pharmaceutical markets, products and companies worldwide.

This easy-to-use, two-volume guide will enable you to: have an instant and informed view of the pharmaceutical industry; understand market trends and estimate market sizes; analyse new products and review recent developments; and assess competitors and their products.

Scrip's 1999 Yearbook is divided into five key sections:
1. Major issues affecting the pharmaceutical industry in 1998, including data on the values of leading markets, new chemical entities and new product developments.
2. Cross-industry statistics drawing together data on the size and estimated growth of world markets, the top-ranked products and companies, R&D expenditure and launch times.
3. Actual revenues and sales forecasts for therapeutic markets worldwide, and information on patient populations.
4. Financial and other information about 30 of the leading companies worldwide as listed by Scrip's 1998 Pharmaceutical Company League Tables.
5. Valuable industry and market data on individual countries and regions.

CONTENTS: Volume 1

Part I: REVIEW OF 1998

1.1: The best and the worst of 1998
1.2: Harmonisation bulldozer rumbles across Europe
1.3: Crisis hits Central and Eastern Europe
1.4: Impeachment process distracts US Congress
1.5: Industry reacts to Asia's economic watershed
1.6: Slow but steady for world pharma sales
1.8: Merck accelerates, Glaxo falters
1.9: Deals within deals
1.10: Dominated by the urge to merge
1.11: Battered and bruised, but biotech battles on
1.12: Products in 1998 - Viagra steals the show
1.13: New Active Substances in 1997 - quality not quantity counts
1.14: Breakthrough after breakthrough
1.15: New approaches to old conditions
1.16: Boxing clever in 1999

Part II: INDUSTRY OVERVIEW
2.1 MARKET DATA
2.1.1: Pharma Sales in Ten Leading Markets, 1997
2.1.2: World Self-Medication Market, 1997
2.1.3: Market Values for Leading OTC Therapeutic Categories, 1997-2001 .1.4: Market Share of Leading OTC Therapeutic Categories by Region, 1997
2.1.5: Average Per Capita Expenditure on OTCs by Region, 1993-1997
2.1.6: Worldwide Retail Generics Market, 1997 - 2002
2.1.7: Pharmaceutical Sales Forecast, 1998
2.1.8: Sales Forecast by Leading Therapy Class, 1998
2.1.9: Sales Forecast by Growth of Therapy Class, 1998
2.1.10: Sales Forecast for Fast Growing Products, 1998
2.1.11: Comparative Prices Across the European Pharmaceutical Industry, 1997
2.1.12: Leading 20 Products, 1996
2.2: INDUSTRY DATA
2.2.1: Top 25 Pharmaceutical Companies, 1997
2.2.2: Pharmaceutical Companies Forecast to 2005
2.2.3: Leading Pharmaceutical Companies by Market Capitalisation
2.2.4: Approximate Market Values of Major Chemical/Pharmaceutical Groups
2.2.5: US and European Biotechnology Industry Data, 1998
2.2.6: Worldwide Biotechnology Industry Forecasts
2.2.7: European Biotechnology Industry Data, 1997
2.3: R&D
2.3.1: Leading R&D Spenders Worldwide, 1997
2.4: MISCELLANEOUS
2.4.1: Leading Companies' Patent Expiries, 1998 - 2005
2.4.2: Worldwide Pharmaceutical Alliances, 1998
2.4.3: Pharmaceutical and Biotechnology Marketing and Sales Expenditure
2.4.4: Expenditure on Direct to Consumer Pharmaceutical Advertising, 1997 - 1998
2.4.5: UK Pharmaceutical Executive Pay League, 1997
2.4.6: Worldwide Contract Research Organisations Market
2.4.7: Cost of Counterfeit Pharmaceuticals
2.4.8: Worldwide Variations in Drug Retail Prices
2.4.9: US Barriers to EC Trade
2.4.10: Counterfeit Drugs Detected by the WHO, 1982 - 1997
2.4.11: World Health Organisation Report, 1998
2.4.12: World Health Organisation Targets for 2020
2.4.13: Market Value of Combinatorial Compounds, 1997
2.4.14: Pharmacogenomic Clinical Trial Market Forecast to 2005
2.4.15: Forecast for Drugs Based on Genomic Discoveries
2.4.16: Gender Specific Research
2.4.17: Suspected ADRs from Herbal Preparations, 1998

Part III: THERAPEUTICS
3.1: ALIMENTARY/METABOLIC
Diabetes
3.1.1: Worldwide Market for Antidiabetic Products
3.1.2: Forecast for Diabetes in Developing Countries, 2025
3.1.3: Worldwide Diabetic Complications Market, 1996
3.1.4: Occurrence and Treatment of Type 1 Diabetic Complications
3.1.5: Worldwide Sales of Type 2 Diabetes Drugs, 1997
3.1.6: Reduction in Life Expectancy of Type 2 Diabetes Patients
Pancreatitis
3.1.7: Incidence of Acute Pancreatitis
Obesity
3.1.8: Annual Cost of Obesity
Hepatitis
3.1.9: Worldwide Prevalence of Hepatitis B
3.1.10: Global Incidence of Hepatitis C
3.1.11: Worldwide Prevalence of Cirrhosis in Patients With Hepatitis C
Miscellaneous
3.1.12: Prevalence of Dysmotility in Dyspepsia Episodes
3.1.13: Worldwide Market for Dietary Supplements
3.1.14: Infant Mortality due to Malnutrition in Developing Countries
3.1.15: Worldwide Nutraceuticals Market, 1998 - 2001
3.1.16: Market Value of Irritable Bowel Syndrome
3.1.17: Incidence of Crohn's Disease
3.1.18: Market for Liver Disease Products
3.2: BLOOD AND CLOTTING
Haemophilia
3.2.1: Market Value of Replacement Clotting Factors for Haemophilia B
3.2.2: Use of Recombinant Factor VIII Products in Haemophilia Patients
Septic Shock
3.2.3: Prognosis for Septic Shock
Thrombosis
3.2.4: Annual Number of Procedures to Diagnose Acute Venous Thrombosis
Miscellaneous
3.2.5: Worldwide Hypolipaemics Market
3.2.6: Worldwide Prevalence of Fabry's Disease
3.2.7: World Market for Warfarin Sodium
3.2.8: Worldwide Market for Thrombopoietin Products
3.2.9: Cases of Heparin-Induced Thrombocytopenia Type II
3.3: CANCER
3.3.1: Global Forecast for Cancer, 2020
3.3.2: The Role of Matrix Metalloproteinases in Cancer
Breast Cancer
3.3.3: Worldwide Breast Cancer Mortality, 1996
3.3.4: Prevalence of Hormone-Sensitive Breast Cancers
3.3.5: Bone Metastases and Breast Cancer
3.3.6: HER-2 Over-Expression in Breast Cancer Patients
3.3.7: Benefits of Chemotherapy for Breast Cancer
Colorectal Cancer
3.3.8: Incidence of Colorectal Cancer in the Developed World
Brain Tumours
3.3.9: Prevalence of Malignant Gliomas
Lung Cancer
3.3.10: Number of Patients with NSCLC Receiving Chemotherapy
3.3.11: Prevalence of Squamous Cell Carcinoma in NSCLC Patients
Ovarian Cancer
3.3.12: Worldwide Incidence of Ovarian Cancer
3.3.13: Prevalence of Hereditary Ovarian Cancer in Women with BRCA1 Mutations
Prostate Cancer
3.3.14: Prevalence of Prostate Cancer in the Over 50s
3.3.15: Number of Hormone Refractory Prostate Cancer Patients
Miscellaneous
3.3.16: Incidence of Cachexia in Europe and the US
3.3.17: Worldwide Incidence of Head and Neck Cancers
3.3.18: Prevalence of Non-Hodgkin's Lymphoma
3.3.19: Incidence of Chronic Lymphocytic Leukaemia
3.3.20: Survival Rate in Patients with Early (stage III) Metastatic Disease
3.3.21: Mortality Rate in Multiple Myeloma Patients
3.3.22: Leading Primary Bone Tumour in Paediatric Patients
3.3.23: Cytostatic Drug Market Value
3.3.24: Role of Telomerase in Tumour Development
3.4: CARDIOVASCULAR
Angina
3.4.1: Unstable Angina: Cause and Treatment
Cardiac
3.4.2: Market for Heart Failure Treatments
3.4.3: Use of Spironolactone in the Treatment of Heart Failure
3.4.4: Incidence of Peripheral Arterial Disease
Hypertension
3.4.5: Calcium Antagonist Market
3.4.6: Incidence of Intradialytic Hypotension in Haemodialysis Patients
Surgery
3.4.7: Cardiac Complications of Surgery in Coronary Heart Disease Patients
3.4.8: Incidence of Restenosis Following Coronary Angioplasty
3.4.9: Incidence of Atrial Fibrillation in Patients Following Heart Surgery
3.4.10: Worldwide Use of Cardiac Stents in Angioplasty
Miscellaneous
3.4.11: Incidence of Minor Heart Valve Leakage
3.4.12: Worldwide Incidence of Venous Leg Ulcers
3.5: DERMATOLOGICAL
3.5.1: Worldwide Market Value for High Potency Topical Steroids
3.5.2: World Market for Hereditary Hair Loss
3.6: GENITOURINARY
Contraception
3.6.1: Male Hormonal Contraceptive Market
3.6.2: Worldwide Market for Male Infertility Diagnostic Tests
3.6.3: Awareness of Emergency Contraception
Menstrual Disorders
3.6.4: Prevalence of Premenstrual Disorders
3.6.5: Incidence of Polycystic Ovary Syndrome in Premenopausal Women
Sexual Dysfunction
3.6.6: Prevalence of Sexual Dysfunction
3.6.7: Worldwide Prevalence of Erectile Dysfunction
3.6.8: Market Forecast of Injectable Products for Erectile Dysfunction
Urological
3.6.9: Incontinence - Symptoms and Treatment
3.6.10: Prevalence of Vesicoureteral Reflux in Children
Miscellaneous
3.6.11: Incidence of Chlamydia Trachomatis in the UK, 1996
3.6.12: Incidence of Bacterial Vaginosis in Women of Child-Bearing Age
3.6.13: Worldwide Market for Acute Genital Herpes Therapies
3.7: HORMONAL
3.7.1: Worldwide Hormone Replacement Therapy Market, 1998
3.7.2: Decline in Male Testosterone Levels with Age
3.8: IMMUNOLOGICAL
HIV
3.8.1: Global Incidence of HIV, 1998
3.8.2: Daily Incidence of HIV Infection
3.8.3: Global Prevalence of HIV, 1998
3.8.4: Incidence of HIV in Children, 1997
3.8.5: Number of Pregnant Women with HIV
3.8.6: Worldwide Incidence of Latent Tuberculosis in HIV-Infected People
3.8.7: Incidence of Hepatitis C in the HIV Infected Population
3.8.8: Cost of HIV Treatment, 1995 - 1997
3.8.9: Anti-HIV Drug Regimens, 1998
3.8.10: Potential Market Value for Microbicides in the Prevention of HIV
AIDS
3.8.11: Global Prevalence of HIV/AIDS
3.8.12: Mortality due to AIDS, 1997
3.8.13: Paediatric Mortality due to AIDS, 1970s - 1998
3.8.13: Prevalence of Co-Infection in AIDS Patients
3.8.14: Worldwide Cost of AIDS Treatment
3.8.15: The Impact of AIDS Drug Prices in the Developing World
Transplantation
3.8.16: Ten Year Survival Rate of Kidney Transplants
3.8.17: Complications of Cytomegalovirus Associated with Organ Transplants
3.9: INFECTIOUS DISEASES
General
3.9.1: Annual Number of Deaths From Preventable Diseases
3.9.2: Prevalence of Antimicrobial Resistance for Bacterial Infections
Tuberculosis
3.9.3: Global Incidence of Tuberculosis, 1998 - 2020
3.9.4: Global Pattern of Resistance to Tuberculosis Drugs
3.9.5: Incidence of Tuberculosis Attributable to HIV, 1993-1998
Leprosy
3.9.6: Global Prevalence of Leprosy, 1990-1997
Polio
3.9.7: Worldwide Incidence of Polio
Vaccines
3.9.8: Potential Lives Saved by Full Deployment of Existing Vaccines
3.9.9: Haemophilus Influenza Vaccine in the Developing World
3.9.10: Worldwide Access to Vaccines
Miscellaneous
3.9.11: Incidence of Epstein-Barr Virus in Europe and the US
3.9.12: Worldwide Incidence of Meningitis
3.9.13: Incidence of Staphyloccocus aureus in Neonates
3.9.14: Incidence of Congenital Sucrase Isomaltase Deficiency in Children
3.9.15: Causative Agents of Otitis Media in Children
3.9.16: Prevalence of Buruli Ulcer
3.9.17: Worldwide Mortality due to Pneumococcus Infection
3.9.18: Worldwide Penicillin Production
3.9.19: Worldwide Mortality due to Measles
3.9.20: World Market Forecast for Antifungal Products, 2000
3.9.21: Worldwide Prevalence of Rotavirus
3.9.22: Worldwide Prevalence of Malaria
3.9.23: Worldwide Prevalence of Trachoma
3.10: MUSCULOSKELETAL
Arthritis
3.10.1: Worldwide Prevalence of Rheumatoid Arthritis
3.10.2: Worldwide Market for Arthritis Therapies, 1998 - 2002
Inflammatory Disorders
3.10.3: Annual Number of UK Prescriptions for Non-Steroidal Anti-Inflammatories
3.10.4: Comparative Gastrointestinal Toxicities of Non Steroidal Anti-Inflammatories
Osteoporosis
3.10.5: Osteoporosis Market, 1996 - 2006
3.10.6: Hormone Replacement Therapy Use for Postmenopausal Osteoporosis
3.10.7: Worldwide Prevalence of Paget's Disease
3.10.8: The Effect of Space Travel on the Onset of Osteoporosis
3.11: NEUROLOGICAL
Alzheimer's Disease
3.11.1: Forecast for Alzheimer's Disease in Developed Countries, 2005
3.11.2: Prevalence of the Genetic Mutation A2M
Anxiety
3.11.3: Prevalence of Social Anxiety Disorder
3.11.4: Worldwide Market for Anxiolytics, 1997
Depression
3.11.5: Worldwide Market for Treatment of Depression
3.11.6: Use of Selective Serotonin Re-uptake Inhibitors
Migraine
3.11.7: Worldwide Migraine Market, 1991 - 1997
Multiple Sclerosis
3.11.8: Prevalence of Multiple Sclerosis
3.11.9: Incidence of Multiple Sclerosis Remission
Parkinson's Disease
3.11.10: Worldwide Prevalence of Parkinson's Disease
Psychotic Disorders
3.11.11: Novel Antipsychotics Market
3.11.12: Worldwide Prevalence of Dementia
Schizophrenia
3.11.13: Prevalence of Schizophrenia
3.11.14: Symptom Recurrence in Schizophrenics
3.11.15: Occurrence of Suicide Attempts in Schizophrenics
Stroke
3.11.16: Worldwide Market For Stroke Treatment
Miscellaneous
3.11.17: Worldwide Incidence of Autism
3.11.18: Prevalence of Insomnia
3.11.19: Number of Deaths from BSE and New Variant CJD
3.11.20: Worldwide Local Anaesthetic Market Value
3.11.21: Worldwide Market Value of Nicotine Replacement Products
3.11.22: CNS Drugs in Late Development
3.12: PARASITIC
3.12.1: Worldwide Incidence of Lymphatic Filariasis
3.12.2: Worldwide Potential Threat of Leishmaniasis
3.12.3: Eradication of Dracunculiasis, 1998
3.13: RESPIRATORY
General
3.13.1: Worldwide Respiratory Products Market
Asthma
3.13.2: Prevalence of Paediatric Asthma, 1980 - 1998
3.13.3: Incidence of Asthma in Children of Asthmatics
3.13.4: Forecast for the Incidence of Asthma, 1995 - 2005
3.13.5: Market Forecast for Anti-Asthmatics, 1998-2005
3.13.6: Comparative Daily Costs of Asthma Treatment, 1996-2000
3.13.7: Number of Prescriptions Written for Corticosteroids, 1997
3.13.8: Leukotriene Antagonists for the Treatment of Asthma
3.13.9: Metered-Dose Inhalation Market for Asthma, 1998 - 2000
Allergy
3.13.10: Worldwide Market for Allergen Immunotherapy
Cystic Fibrosis
3.13.11: World Market for Cystic Fibrosis Therapies
3.13.12: Prevalence of Cystic Fibrosis
Respiratory Infections
3.13.13: Worldwide Prevalence of Respiratory Syncytial Virus in Children
3.13.14: Paediatric Mortality from Acute Respiratory Infections in Developing Countries
Miscellaneous
3.13.15: Worldwide Incidence of Chronic Obstructive Pulmonary Disease
3.13.16: Market Value of Treatments for Chronic Obstructive Pulmonary Disease
3.13.17: Number of Known Strains of Human Rhinovirus
3.13.18: Prevalence of Nasal Polyps
3.14: SENSORY
3.14.1: Prevalence of the Genetic Variation GLCE in Glaucoma Patients
3.15: FORMULATIONS
3.15.1: Worldwide Drug Delivery Market, 1998 - 2002
3.16: MISCELLANEOUS
3.16.1: Incidence and Disease Pattern of Mucopolysaccharidosis
3.16.2: Mortality due to Surgical Abortion in Developing Countries
3.16.3: Worldwide Incidence of Hereditary Angioedema
3.16.4: Worldwide Market for Ultrasound Imaging Products
3.16.5: In Vitro Diagnostic Market Value
3.16.6: Antisense Drug Technology

Part IV: COMPANIES
4.1: ABBOTT
Financial Data
4.1.1: Abbott's Financial Data, 1997

4.2: AMERICAN HOME PRODUCTS
Financial Data
4.2.1: American Home Products' Financial Data, 1997
4.2.2: American Home Products' Sales by Division, 1997
4.2.3: American Home Products' Sales by Region, 1997
Product Sales
4.2.4: American Home Products' Leading Product Sales, 1997
4.2.5: Worldwide Use of Norplant
R&D
4.2.6: American Home Products' Pharmaceutical Product Pipeline
Corporate
4.2.7: American Home Products/Monsanto Merger Abandonment, 1998
4.3: AMGEN
Financial Data
4.3.1: Amgen's Financial Data, 1997
4.4: ASTRA
Financial Data
4.4.1: Astra's Financial Data, 1997
4.4.2: Astra's Sales by Therapeutic Category, 1996-1997
4.4.3: Astra-Merck's Sales, 1997
Product Sales
4.4.4: Astra's Leading Product Sales, 1997
4.4.5: Astra's Prescription Sales 1997 - 2003
R&D
4.4.6: Astra's CNS Development Strategy
4.4.7: Astra's Non-CNS Development Pipeline, 1998
Corporate
4.4.8: Astra/Zeneca Merger Details
4.4.9: AstraZeneca Pro forma Results, 1997
4.4.10: AstraZeneca Sales Forecast, 1998 - 2000
4.4.11: AstraZeneca in Japan
4.4.12: AstraZeneca's Key Late Stage Product Pipeline
4.5: BAYER
Financial Data
4.5.1: Bayer's Financial Data, 1997
4.5.2: Bayer's Healthcare Results, 1997
Product Sales
4.5.3: Bayer's Leading Products by Sales, 1997
R&D
4.5.4: Highlights of Bayer's R&D Pipeline
4.5.5: Bayer's R&D Expenditure Forecast, 1998
Corporate
4.5.6: Bayer's Japanese Sales, 1997
4.7: BRISTOL-MYERS SQUIBB
Financial Data
4.7.1: Bristol-Myers Squibb's Financial Data, 1997
4.7.2: Bristol-Myers Squibb's Sales by Therapeutic Category, 1996
Product Sales
4.7.3: Bristol-Myers Squibb's Leading Product Sales, 1996 - 1997
Corporate
4.7.4: Bristol-Myers Squibb's French Sales, 1997
4.7.5: Bristol-Myers Squibb's Spanish Sales, 1997
4.7.6: Bristol-Myers Squibb's Peruvian Subsidiary
4.6: BOEHRINGER INGELHEIM
Financial Data
4.6.1: Boehringer Ingelheim's Financial Data, 1997
Product Sales
4.6.2: Boehringer Ingelheim's Prescription Sales, 1996 - 1997
4.6.3: Boehringer Ingelheim's Forecast Sales of New Products, 1998
R&D
4.6.4: Boehringer Ingelheim's Development Pipeline
Corporate
4.6.5: Boehringer Ingelheim's Japanese Sales, 1997
4.6.6: Highlights of Boehringer Ingelheim's Japanese Product Pipeline, 1998
4.8: EISAI
Financial Data
4.8.1: Eisai's Financial Data, 1997/98
4.8.2: Eisai's Sales by Therapeutic Category, 1996/97
Product Sales
4.8.3: Eisai's Leading Products, 1997/98
R&D
4.8.4: Eisai's Product Pipeline in Japan
Corporate
4.8.5: Eisai's Sales Forecast, 1998 - 2001
4.9: GLAXO WELLCOME
Financial Data
4.9.1: Glaxo Wellcome's Financial Data, 1997
4.9.2: Glaxo Wellcome's Sales by Therapeutic Area, 1997
Product Sales
4.9.3: Sales Forecasts for Glaxo Wellcome's Leading Products, 1997-2000
4.9.4: Glaxo Wellcome's Respiratory Product Sales in the US, 1998
4.9.5: Glaxo Wellcome's Growth Strategy for Respiratory Products
R&D
4.9.6: Glaxo Wellcome's Late-Stage Development Pipeline
Corporate
4.9.7: Glaxo India's Sales, 1997
4.9.8: Glaxo Wellcome's Mexican Sales, 1997
4.9.9: Glaxo Wellcome's Brazilian Sales Forecast, 1998
4.9.10: Glaxo Wellcome's Share of the Egyptian Pharmaceutical Market
4.10: HOECHST MARION ROUSSEL
Financial Data
4.10.1: Hoechst's Financial Data, 1997
4.10.2: Hoechst Marion Roussel's Financial Data, 1996 - 1997
Product Sales
4.10.3: Hoechst Marion Roussel's Leading Products, 1997
R&D
4.10.4: Highlights of Hoechst Marion Roussel's Late-stage Development Pipeline
Corporate
4.10.5: Hoechst Marion Roussel's Financial Forecast, 1998
4.10.6: Hoechst Marion Roussel's Thai Sales, 1997
4.10.7: Hoechst and Rhône-Poulenc Merger Details
4.10.8: Highlights of Aventis' Key Late-stage Development Programmes
4.10.9: Aventis' R&D Forecast
4.10.10: Details of Aventis' Japanese Operations

4.11: JOHNSON & JOHNSON
Financial Data
4.11.1: Johnson & Johnson's Financial Data, 1997
4.11.2: Johnson & Johnson's Sales by Business Segment, 1997
4.11.3: Johnson & Johnson's Sales by Region, 1997
4.11.4: Johnson & Johnson's R&D Expenditure, 1998
Corporate
4.11.5: Janssen's Japanese Activities, 1997
4.11.6: Johnson & Johnson's Russian Sales
4.12: KNOLL/BASF
Financial Data
4.12.1: BASF's Financial Data, 1997
4.12.2: BASF Pharma's Sales, 1994 - 1998
R&D
4.12.3: Knoll's Compounds in Development
4.12.4: Sales Potential of BASF Pharma's Late Development Pipeline
4.12.5: BASF's Japanese Product Pipeline
4.12.6: Knoll's R&D Collaborations
Corporate
4.12.7: Knoll Pharmaceuticals' Indian Sales, 1997
4.13: LILLY
Financial Data
4.13.1: Lilly's Financial Data, 1997
4.13.2: Lilly's Sales by Therapeutic Category, 1997
Product Sales
4.13.3: Lilly's Leading Products by Sales, 1997
Corporate
4.13.4: Lilly's Korean Sales Forecast, 1998
4.13.5: Lilly's Aims Outside the US, 1998 - 2000
4.14: MERCK & CO
Financial Data
4.14.1: Merck & Co's Financial Data, 1997
4.14.2: Merck's Sales by Therapeutic Category, 1997
Product Sales
4.14.3: Merck's Leading Product Sales, 1997
4.14.4: US Sales of Merck's Leading Products, 1997
R&D
4.14.5: Merck's R&D Forecast, 1999
Corporate
4.14.6: Merck-Medco's Growth Rate, 1997 - 1998
4.15: NOVARTIS
Financial Data
4.15.1: Novartis' Financial Data, 1997
4.15.2: Novartis' Sales by Division, 1997
R&D
4.15.3: Highlights of Novartis' R&D Pipeline, 1998
Corporate
4.15.4: Novartis' Japanese Sales, 1997
4.15.5: Highlights of Novartis' Japanese R&D Pipeline
4.15.6: Novartis' Spanish Sales, 1997
4.15.7: Novartis' Italian Sales, 1997

4.16: PHARMACIA & UPJOHN
Financial Data
4.16.1: Pharmacia & Upjohn's Financial Results, 1997
4.16.2: Pharmacia & Upjohn Sales by Region, 1997
4.16.3: Pharmacia & Upjohn's Sales by Therapeutic Category, 1997
Product Sales
4.16.3: Pharmacia & Upjohn Leading Product Sales, 1997
4.16.4: Pharmacia & Upjohn's Sales Forecast for Detrol, 1998 - 1999
R&D
4.16.5: Pharmacia & Upjohn's Late Stage Development Pipeline
Corporate
4.16.6: Pharmacia & Upjohn's Financial Forecast, 1998-2003
4.17: PFIZER
Financial Data
4.17.1: Pfizer's Financial Data, 1997
4.17.2: Pfizer's Sales by Therapeutic Category, 1997
Product Sales
4.17.3: Pfizer's Leading Product Sales, 1997
R&D
4.17.4: Highlights of Pfizer's Late Development Pipeline
Corporate
4.17.5: Pfizer's Japanese Sales, 1997
4.17.6: Pfizer's Malaysian Sales
4.17.7: Pfizer's South Korean Sales, 1997
4.17.8: Pfizer's UK Investments
4.18: RHÔNE-POULENC RORER
Financial Data
4.18.1: Rhône-Poulenc's Financial Data, 1997
4.18.2: Rhône-Poulenc's Pharma Activities, 1996-1997
Product Sales
4.18.3: Rhône-Poulenc Rorer's Leading Product Sales, 1997
R&D
4.18.4: Highlights of Rhône-Poulenc's R&D Pipeline
Corporate
4.18.5: Hoechst and Rhône-Poulenc Merger Details
4.18.6: Highlights of Aventis' Key Late-stage Development Programmes
4.18.7: Aventis' R&D Forecast
4.18.8: Details of Aventis' Japanese Operations
4.19: ROCHE
Financial Data
4.19.1: Roche's Financial Data, 1997
4.19.2: Roche's Sales by Therapeutic Category, 1997
Product Sales
4.19.3: Roche's Leading Products, 1997
4.20: SANKYO
Financial Data
4.20.1: Sankyo's Financial Data, 1997/98
Product Sales
4.20.2: Sankyo's Leading Products, 1997/98
R&D
4.20.3: Sankyo's Product Pipeline in Japan

4.21: SANOFI
Financial Data
4.21.1: Sanofi's Financial Results, 1997
4.21.2: Sanofi's Sales by Therapeutic Category, 1997
Product Sales
4.21.3: Sanofi's Leading Product Sales, 1997
R&D
4.21.4: Highlights of Sanofi's R&D Pipeline
Corporate
4.21.5: Sanofi-Synthélabo Merger Details
4.21.6: Sanofi-Synthélabo's Position in Europe
4.21.7: Sanofi-Synthélabo's R&D Portfolio
4.21.8: Sanofi's Hungarian Sales and Activities, 1997
4.22: SCHERING AG
Financial Data
4.22.1: Schering AG's Financial Figures, 1997
4.22.2: Schering's Sales by Region, 1997
4.22.3: Schering's Sales by Category, 1997
Product Sales
4.22.4: Schering's Leading Product Sales, 1997-2003
Corporate
4.22.5: Schering's Market Forecast, 1998
4.22.6: Schering AG's Thai Sales Forecast, 1998
4.23: SCHERING-PLOUGH
Financial Data
4.23.1: Schering-Plough's Sales Data, 1997
4.23.2: Schering-Plough's Sales by Therapeutic Category, 1997
Product Sales
4.23.3: Schering-Plough's Leading Products Sales, 1997
Corporate
4.23.4: Schering-Plough's Mexican Sales, 1997
4.24: SEARLE
Financial Data
4.24.1: Searle's Financial Data, 1997
4.24.2: Monsanto's Sales Breakdown, 1997 - 1999
R&D
4.24.3: Monsanto Pharmaceutical Product Pipeline
Corporate
4.24.4: Monsanto/American Home Products Merger Abandonment, 1998
4.25: SHIONOGI
Financial Data
4.25.1: Shionogi's Financial Data, 1997/98
4.25.2: Shionogi's Sales by Therapeutic Category, 1997/98
Product Sales
4.25.3: Shionogi's Leading Product Sales, 1997/98
4.26: SMITHKLINE BEECHAM
Financial Data
4.26.1: SmithKline Beecham's Financial Data, 1997
4.26.2: SmithKline Beecham's Sales Breakdown, 1997
Product Sales
4.26.3: SmithKline Beecham's Leading Products, 1997
4.26.4: Forecasts for SmithKline Beecham's Leading Products, 1997-2000
4.26.5: Sales Forecast for Avandia
R&D
4.26.6: SmithKline Beecham's Late-Stage Development Pipeline
4.26.7: SmithKline Beecham's Pharmaceutical R&D Portfolio
4.26.8: Vaccines in Development at SmithKline Beecham
4.27: TAKEDA
Financial Data
4.27.1: Takeda's Financial Data, 1997/98
Product Sales
4.27.2: Takeda's Leading Products, 1997/98
Corporate
4.27.3: Takeda's Financial Aims, 1998 - 2000
4.28: WARNER-LAMBERT
Financial Data
4.28.1: Warner-Lambert's Financial Data, 1997
Product Sales
4.28.2: Warner-Lambert's Leading Product Sales, 1997
4.28.3: Sales Forecast for Lipitor, 1998 - 2002
R&D
4.28.4: Warner-Lambert's Pharmaceutical R&D Portfolio
Corporate
4.28.5: Warner-Lambert's Financial Forecasts, 1998 - 1999
4.29: YAMANOUCHI
Financial Data
4.29.1: Yamanouchi's Financial Data, 1997/98
4.29.2: Yamanouchi's Sales by Therapeutic Category, 1997/98
Product Sales
4.29.3: Yamanouchi's Leading Product Sales, 1997/98
4.29.4: Yamanouchi's Sales Forecast for Tamsulosin, 1998/99
Corporate
4.29.5: Yamanouchi's Taiwanese Sales, 1997/98
4.30: ZENECA
Financial Data
4.30.1: Zeneca's Financial Data, 1997
4.30.2: Zeneca's Sales by Therapeutic Category, 1997
4.30.3: Zeneca's Pharmaceutical Sales by Market, 1997
Product Sales
4.30.4: Zeneca's Pharmaceutical Sales by Product Area, 1997
4.30.5: Zeneca's Leading Product Sales, 1997
R&D
4.30.6: Zeneca's Japanese R&D Pipeline
Corporate
4.4.8: Astra/Zeneca Merger Details
4.4.9: AstraZeneca Pro forma Results, 1997
4.4.10: AstraZeneca Sales Forecast, 1998 - 2000
4.4.11: AstraZeneca in Japan
4.4.12: AstraZeneca's Key Late Stage Product Pipeline
4.30.12: Zeneca's Spanish Sales, 1997
4.30.13: Zeneca's Japanese Sales, 1997

CONTENTS - Volume 2
5.1: AFRICA
General
5.1.1: Incidence of the Ebola and Marburg Viruses in Africa
5.1.2: Forecast for Onchocerciasis in Africa, 2002
5.1.3: Prevalence of HIV in the Ivory Coast and Uganda
Benin
5.1.4: Prophylactic Vaccination in Benin, 1991 - 1996
Egypt
5.1.5: Pharmaceutical Production in Egypt
Morocco
5.1.6: Moroccan Pharmaceutical Production, 1997
Nigeria
5.1.7: Nigerian Health Budget, 1998
South Africa
5.1.8: South African Generics Market Value
5.1.9: Incidence and Prevalence of HIV in South Africa
5.1.10: Incidence of HIV in the South African Antenatal Population, 1997
5.1.11: Number of Traditional Healers in South Africa
Zambia
5.1.12: Prescription of Antibiotics in Zambia
Zimbabwe
5.1.13: Forecast for Life Expectancy in Zimbabwe, 2000
5.1.14: Prevalence of HIV/AIDS in Zimbabwe
5.2: AMERICA - NORTH
Canada
Market Data
5.2.1: Canadian Sales of Prescription Drugs by Therapeutic Category, 1997
5.2.2: Canadian Drug Sales, 1997
5.2.3: OTC Sales in Canada, 1997
5.2.4: Drug Expenditure in Ontario, 1996 - 1997
5.2.5: Drug Expenditure in Quebec, 1996 - 1997
5.2.6: Canadian Drug Prices, 1997
5.2.7: Prescription of Calcium Channel Blockers in Canada, 1994 - 1996
Industry Data
5.2.8: The Ten Leading Companies by Sales in Canada, 1997
5.2.9: Canadian R&D Expenditure, 1997
5.2.10: Canadian R&D Expenditure by Province, 1988-1996
Regulation
5.2.11: Leading 10 Companies by Reimbursement Expenditure in Canada, 1997
5.2.12: Top 10 Drugs by Reimbursement Expenditure in Canada, 1997
5.2.13: Average Time for New Drug Approvals in Canada, 1996
5.2.14: Canadian Drug Patent Regulation, 1998
5.2.15: Canadian Expenditure on Pharmaceuticals for Benefit Recipients, 1997
5.2.16: Canadian Provincial Drug Expenditure, 1997
5.2.17: Generic Drug Reimbursement in Ontario, 1998
Therapeutic Data
5.2.18: Forecast for the Incidence of Stroke in Canada
5.2.19: Prevalence of Relapsing Multiple Sclerosis in Canada
5.2.20: Prevalence of Hepatitis B Infection in Canada
5.2.21: Incidence of Chickenpox in Canada
United States of America
Market Data
5.2.22: Value of the US Pharmaceutical Market, 1997
5.2.23: The Ten Leading US Therapeutic Categories, 1997
5.2.24: The Ten Leading US Growth Categories, 1997
5.2.25: Leading Products by US Sales, 1997
5.2.26: Ten Leading New Products Launched in the US, 1997
5.2.27: US Comparative Formulary Acceptance Levels for New Products, 1997
5.2.28: Prescriptions Dispensed in the US, 1997
5.2.29: US Manufacturer Sales of Prescription Drugs by Distribution Channel, 1996 - 1997
5.2.30: Leading Products by Number of US Prescriptions Dispensed, 1997
5.2.31: US Prescription Drug Prices, 1993 - 1997
5.2.32: US Producer Price Index for Pharmaceuticals, 1988 - 1997
5.2.33: US Retail Prescriptions, 1998
5.2.34: US Prescription Market Growth, 1995-1996
5.2.35: US Retail Drug Sales Forecast, 1998
5.2.36: Generic and Branded Product Sales in US Drugstores, 1996
5.2.37: Drug Prices in the US vs Canada and Mexico
5.2.38: Mail-Order Medicines in the US, 1998
5.2.39: US Pharmaceutical Trade Deficit, 1995 - 1998
5.2.40: Annual Cost of Trade Barriers to the US
Industry Data
5.2.41: Ranking of Companies by US Drug Sales, 1997
5.2.42: Ranking of Companies by Prescriptions Dispensed, 1997
5.2.43: Leading US Pharmaceutical Groups by Market Capitalisation, 1997
5.2.44: Leading Pharmaceutical Groups in the Super 500 Ranking, 1997
5.2.45: Super 500 Pharmaceutical Companies, 1997
5.2.46: US Pharma Groups' Profitability, 1997
5.2.47: US Company Financial Results, 1997
5.2.48: Leading US Companies by Shareholder Return, 1997
5.2.49: US Company Promotional Activity, 1994-1997
5.2.50: Company Salesforce Ratings by US Physicians, 1997
5.2.51: Company Salesforce Ratings by US Managed Care Executives, 1997
5.2.52: PhRMA Member Company Sales, 1997
5.2.53: US Physicians' Ranking of Pharmaceutical Companies
5.2.54: Major US Companies' R&D Expenditure, 1996-1998
5.2.55: US Drug Companies CEO Compensation, 1997
5.2.56: Top Ten US Pharmaceutical Wholesalers by Sales, 1996
5.2.57: Leading Pharma Distributors in the US Super 500, 1997
5.2.58: Drug Prices in the US, 1998
5.2.59: New Molecular Entities Approved in the US in 1997
5.2.60: US Mean Approval Time for New Drugs, 1997
5.2.61: US Biotechnology Industry Data, 1997
5.2.62: Price Differential of Leading Brand-Name Drugs Prescribed for US Elderly
Regulation
5.2.63: US Advertisement Expenditure by Disease Class, 1997
5.2.64: FDA Budget, 1999
5.2.65: US FDA Financial Disclosure Regulations, 1998
5.2.66: Approval Times for Abbreviated New Drug Applications in the US
5.2.67: Number of Generic Drugs Approved by the OGD, 1997
5.2.68: FDA Inspections of Foreign Manufacturers

Therapeutic Data
5.2.69: Leading Therapeutic Categories in the US, 1997/98
Alimentary/Metabolic
5.2.70: US Obesity Market
5.2.71: US Dietary Supplement Market Value
5.2.72: Prevalence of Type 2 Non-insulin Dependent Diabetes in the US
5.2.73: Prevalence of Diabetic Neuropathy in the US
5.2.74: Prevalence of Hepatitis B in the US
5.2.75: Prevalence of Hepatitis C in the US
5.2.76: Prevalence of Crohn's Disease in the US
5.2.77: Incidence of Fistulising Crohn's Disease in the US
5.2.78: Prevalence of Irritable Bowel Syndrome in the US
5.2.79: Prevalence of Periodontal Disease in the US
5.2.80: Incidence of Acute Renal Failure in Patients Undergoing Major Surgery in the US
Blood and Clotting
5.2.81: US Market for Proton Pump Inhibitors, 1998 - 2001
5.2.82: US Thrombolytic Market Value
5.2.83: US Clotbusting Market, 1997
5.2.84: Incidence of Sickle Cell Anaemia in the US
5.2.85: Prevalence of Haemophilia A in the US
5.2.86: Annual Number of High Blood Loss Operations in the US
5.2.87: Number of Platelet Transfusions in the US
5.2.88: US Market for Warfarin
5.2.89: Incidence of Allergic Reaction to Heparin in the US
Cancer
5.2.90: Incidence of Breast Cancer in the US
5.2.91: Number of US Women at High Risk of Breast Cancer
5.2.92: Incidence of Metastatic Breast Cancer with HER2 Overexpression
5.2.93: Incidence of Lung Cancer in the US
5.2.94: Incidence of Small-Cell-Lung Cancer in the US
5.2.95: Incidence of Non-Small-Cell Lung Cancer in the US
5.2.96: Incidence of B-cell Lymphoma in the US, 1998
5.2.97: Prevalence of Low-Grade Non-Hodgkin's Lymphoma in the US
5.2.98: Frequency of Melanoma in US Women
5.2.99: Incidence of Myelogenous Leukaemia in the US
5.2.100: Incidence of Pancreatic Cancer in the US
5.2.101: US Incidence of Prostate Cancer, 1998
5.2.102: Prevalence of Refractory Bladder Cancer in the US
5.2.103: Incidence of Colorectal Cancer in the US
5.2.104: Prevalence of Ewing's Sarcoma in US Caucasian Children
5.2.105: Incidence of Actinic Keratosis
5.2.106: Incidence of Cutaneous T-Cell Lymphoma in the US
5.2.107: Prevalence of Breakthrough Cancer Pain in the US
Cardiovascular
5.2.108: Annual Incidence of Various Cardiovascular Disorders in the US
5.2.109: Incidence of Unstable Angina in the US
5.2.110: Prevalence of Atrial Fibrillation in the US
5.2.111: Number of Cardiac Stent Procedures in the US, 1997
5.2.112: Incidence of Aspirin Resistance in the US Heart Attack and Stroke Population
Dermatological
5.2.113: US Market for Severe Dermatoses
5.2.114: Incidence of Psoriasis in the US
5.2.115: Incidence of Scalp Psoriasis in the US
5.2.116: US Market for the Treatment of Diabetic Foot Ulcers
5.2.117: Incidence of Alopecia Areata in the US
Genitourinary
5.2.118: US Incontinence Market
5.2.119: Incidence of Unintended Pregnancy in the US
5.2.120: US Emergency Oral Contraception Market
Infectious Diseases
5.2.121: Incidence of Influenza in the US
5.2.122: Incidence of Tuberculosis in the US, 1997
5.2.123: US Market for Diphtheria, Tetanus and Acellular Pertussis Vaccines
5.2.124: Incidence of Meningitis B in the US
5.2.125: US Ear Infections Market
5.2.126: Number of US Doctor Visits as a Result of Acute Otitis Media, 1997
Immunological
5.2.127: Number of HIV-Positive Patients Receiving Treatment in the US
5.2.128: Prevalence of Kaposi's Sarcoma in the US
5.2.129: Incidence of Non-Compliance Amongst Transplant Recipients in the US
5.2.130: Number of Patients Undergoing Antiretroviral Therapy in the US
Musculoskeletal
5.2.131: Prevalence of Rheumatoid Arthritis in the US
5.2.132: Prevalence of Juvenile Rheumatoid Arthritis in the US
5.2.133: US Market for Non-Steroidal-Anti-Inflammatories
5.2.134: Number of NSAI-related Hospitalisations and Deaths in the US
5.2.135: Prevalence of Undiagnosed Low Bone Mass in US Women Over 50
5.2.136: US Generic Market for Diclofenac
Neurological
5.2.137: Prevalence of Anxiety in the US
5.2.138: US Antidepressant Market Value, 1997 - 2002
5.2.139: US Selective Seratonin Re-uptake Inhibitor Market, 1997 - 1998
5.2.140: US Antipsychotic Market
5.2.141: Prevalence of Post-traumatic Stress Disorder in the US
5.2.142: US Stroke Market Value
5.2.143: US Market for Adult Analgesics
5.2.144: US Migraine Market
5.2.145: Prevalence of Parkinson's Disease in the US
5.2.146: Prevalence of Multiple Sclerosis in the US
5.2.147: Cases of Severe Head Trauma in the US
5.2.148: Incidence of Motion Sickness in the US
5.2.149: Incidence of Intractable Pain in the US
5.2.150: US Market for Carbamazepine
5.2.151: Prevalence of Sleep Apnoea in the US
5.2.152: Prevalence of Narcolepsy in the US
5.2.153: Incidence of Subarachnoid Haemorrhage in the US
5.2.154: Number of Heavy Drinkers in the US
Parasitical
5.2.155: US Incidence of Lyme Disease, 1982 - 1996
5.2.156: Leading Antihistamines by US Market Share, 1997
Respiratory
5.2.157: Prevalence of Cystic Fibrosis in the US
5.2.158: Incidence of Croup in the US
5.2.159: Prevalence of Meconium Aspiration Syndrome in the US
5.2.160: US Inhaled Albuterol Market Value
Sensory
5.2.161: Prevalence of Sj”gren's Syndrome in North America
5.2.162: US Market for Sodium Hyaluronate Products in Ophthalmic Surgery
Miscellaneous
5.2.163: US Market for Gene Discovery Software
5.2.164: Incidence of the Mutant HFE Gene in the US

5.3: AMERICA - CENTRAL AND SOUTH
Latin America
Market Data
5.3.1: Latin American Pharmaceutical Market Values, 1997
5.3.2: Latin American Expenditure on Medicines by Country
5.3.3: Availability of Medicines in Latin America
Industry Data
5.3.4: Latin American OTC Industry Sales, 1997
5.3.5: Approval Times for Clinical Trials in Latin America
5.3.6: The Regulatory Environment for Clinical Trials in Latin America
5.3.7: Vaccine Production in Latin America and the Caribbean
Argentina
5.3.8: Argentinian Pharmaceutical Market
5.3.9: Leading 20 Pharmaceutical Companies in Argentina, 1997
5.3.10: Top 16 Argentinian Pharmaceutical Exporters, 1997
Brazil
Market Data
5.3.11: Brazilian Pharmaceutical Sales, 1997
5.3.12: Brazilian Sales of Leading Osteoporosis Products, 1992 and 1996
5.3.13: Brazilian Market for Medicines for the Elderly
5.3.14: Brazilian Pharmaceutical Distribution
Industry Data
5.3.15: Brazilian Pharmaceutical Exports, 1997 - 1998
5.3.16: Brazilian Government Expenditure on AIDS Medicines, 1998
5.3.17: Cost of Antiretroviral Treatment for AIDS in Brazil
5.3.18: Brazilian Contraceptive Market, 1997
5.3.19: Cases of Impotence in Brazil
Miscellaneous
5.3.20: Theft of Medicines in Brazil, 1997
Chile
5.3.21: Chilean Pharmaceutical Industry Data
5.3.22: Chilean Bioequivalent Generic Market
5.3.23: Multinational Expenditure on Product Development in Chile
Colombia
5.3.24: Colombian Pharmaceutical Market Value, 1997
Cuba
5.3.25: Cuban and US Trade Data, 1980 - 1998
Mexico
5.3.26: Medicines in Mexico
5.3.27: Mexican Pharmaceutical R&D Funding
Peru
5.3.28: Peruvian Pharmaceutical Market Data, 1998
5.3.29: Peruvian Retail Pharmaceutical Market Value
5.4: AUSTRALASIA
Australia
Industry Data
5.4.1: Australian Pharmaceutical Industry Data, 1996-97
Regulation
5.4.2: Australian Government Pharmaceutical Expenditure, 1998 - 2020
5.4.3: Top 10 Products in Terms of Cost to the Australian Government, 1997
5.4.4: Australian Reference Pricing Regimen, 1997
5.4.5: Australian Expenditure on HIV and AIDS Treatments, 1997
Therapeutic Data
5.4.6: Prevalence of HIV in Australian Women of Childbearing Age
5.4.7: Prevalence of Alcohol Abuse and Related Disorders in Australia
New Zealand
Regulation
5.4.8: New Zealand Health Expenditure, 1998
5.4.9: Pharmac's Expenditure by Therapeutic Category, 1998
5.4.10: New Zealand Healthcare Expenditure on the Elderly
5.4.11: New Zealand Price Reductions, 1997 - 1998
5.4.12: Number of Prescriptions Written for Prozac in New Zealand, 1996-1997
5.4.13: Use of Subsidised Statins in New Zealand, 1998
Therapeutic Data
5.4.14: Prevalence of Obesity in New Zealand
5.4.15: Use of ACE-inhibitors in New Zealand
5.4.16: Prevalence of Chronic Hepatitis B in New Zealand
5.4.17: Paediatric Cases of Hepatitis B in New Zealand, 1993 - 1997
5.4.18: Prevalence of Herpes in New Zealand
5.4.19: Prevalence of Shingles in New Zealand
5.5: EUROPE
Market Data
5.5.1: European OTC Market Data, 1991 - 1997
5.5.2: Potential Savings from Self-Medication in EU Countries
5.5.3: The European Generics Market, 1996-97
Industry Data
5.5.4: Leading Pharmaceutical Companies by European Market Share
5.5.5: Leading European Pharmaceutical Companies by Market Capitalisation
5.5.6: Leading Wholesalers in Europe by Market Share, 1998
Regulation
5.5.7: EMEA Mutual Recognition Applications, 1997
5.5.8: EMEA Financial Report, 1997
5.5.9: Marketing Applications Under the Centralised Approval Procedure, 1995-1997
5.5.10: Frequency of Reference Member Status for EC Mutual Recognition, 1995 - 1997
5.5.11: Frequency of Rapporteur Applications for EC Centralised Procedures, 1997
5.5.12: Supplementary Protection Certificates Issued in EU Countries, 1997
5.5.13: Average Marketing Authorisation Times in the European Union
5.5.14: Delays Between Drug Approval and Marketing in the EC, 1996 - 1997
5.5.15: EC Patents Filed by South Korean and Russian Companies, 1986 - 1995
5.5.16: EMEA Fee Exemptions for Orphan Drugs, 1995 - 1998
5.5.17: European Commission Complaints to the World Trade Organisation, 1997
5.5.18: European Evaluation of Medical Technology in Practice
5.5.19: EC Biomedical and Health Research Programme, 1994-1998
Therapeutic Data
5.5.20: European HIV/AIDS Market, 1997 - 2004
5.5.21: Incidence of HIV-Infection in the European Union
5.5.22: European Osteoporosis Market, 1996-2003
5.5.23: Forecast for Alzheimer's Disease in the EC, 2000
5.5.24: Prevalence of Non-Hodgkin's Lymphoma in Europe
Austria
5.5.25: Austrian Drug Pricing and Reimbursement System, 1998
5.5.26: Austrian Healthcare Expenditure on Antibiotics, 1992-1996
5.5.27: Medicine Expenditure by the Austrian Health Insurance Sector, 1996
Belgium
Industry Data
5.5.28: The Biotechnology Industry in Belgium
Regulation
5.5.29: Belgian Pharmaceutical Budget, 1998 - 1999
5.5.30: Belgian Reimbursement Times, 1997 - 1998
5.5.31: Approval Time for Pharmaceutical Products in Belgium, 1997
5.5.32: Belgian Health Insurance Expenditure, 1997
Central And Eastern Europe
5.5.33: Central and Eastern European OTC Market, 1997
5.5.34: Central and Eastern European OTC Sales, 1992-1996
5.5.35: Clinical Trial Practice in Central and Eastern Europe
5.5.36: Clinical Trial Expenses in Central and Eastern Europe
5.5.37: Effective Dates of Product Patent Protection in Central and Eastern Europe
5.5.38: Inappropriate Drug Donation in Bosnia and Herzogovina
Bulgaria
5.5.39: Bulgarian Pharmaceutical Market, 1997
5.5.40: The Pharmaceutical Industry in Bulgaria, 1998
5.5.41: Prevalence of Breast Cancer in Bulgaria
5.5.42: Number of Migraine Sufferers in Bulgaria
Czech Republic/Slovak Republic
5.5.43: Value of Czech and Slovak OTC Markets, 1994-1997
5.5.44: Leading Therapeutic Categories in the Czech and Slovak OTC Market, 1997
5.5.45: Leading Therapeutic Categories in the Czech OTC Market, 1997
5.5.46: Slovak Healthcare Budget, 1998
5.5.47: Prevalence of Glaucoma in the Czech Republic
Hungary
5.5.48: Leading Therapeutic Categories in the Hungarian OTC Market, 1997
5.5.49: Hungarian Pharmaceutical Expenditure, 1998
Poland
5.5.50: Polish OTC Market, 1991 - 1998
5.5.51: Major Pharmaceutical Companies in Poland, 1997
5.5.52: Cost of Implementing GMP Standards in Poland
Romania
5.5.53: Romanian Pharmaceutical Market, 1997
5.5.54: Leading Therapeutic Categories in the Romanian OTC Market, 1997
5.5.55: Leading Pharmaceutical Companies in Romania, 1997
5.5.56: Romanian Marketing Authorisation Times, 1996 - 2000
France
Market Data
5.5.57: French Pharmaceutical Market Data, 1997
5.5.58: French Pharmaceutical Product Data, 1997
5.5.59: New Products in France, 1997
5.5.60: French Pharmaceutical Market Share by Therapeutic Category, 1997
5.5.61: Medicine Consumption in France, 1997 - 1998
5.5.62: Longevity of Drugs on the French Market, 1997
5.5.63: Concentration of the French Pharmaceutical Market, 1995
5.5.64: French Sales of Antibiotics, 1991 - 1996
5.5.65: Number of Companies Marketing Generic Medicines in France, 1997
Industry Data
5.5.66: French Pharmaceutical Industry Sales, 1997
5.5.67: Pharmaceutical Rankings of Leading Companies in France, 1997
5.5.68: Promotional Expenditure by the French Pharmaceutical Industry, 1996
5.5.69: French Wholesaling Levy, 1996 - 1998
5.5.70: French Pharmacists' Mark-up Percentages, 1991 - 1998
Regulation
5.5.71: Forecast for French Healthcare Insurance Expenditure, 1998 - 1999
5.5.72: French Community Expenditure, 1999
5.5.73: French Healthcare Expenditure, 1998
5.5.74: French Pharmaceutical Expenditure, 1997
5.5.75: French National Health Insurance Healthcare Reimbursement, 1997
5.5.76: French Reimbursement Times, 1997
5.5.77: French Drug Approvals by Product Category, 1996 - 1997
5.5.78: French Adverse Drug Reaction Reports, 1997
5.5.79: French Prescribing Guidelines, 1993 - 1998
Therapeutic Data
5.5.80: Mortality in Hepatitis B Patients in France
5.5.81: Hepatitis B Vaccinations in France, 1989 - 1996
5.5.82: Use of Intrauterine Contraceptive Devices in France
5.5.83: Incidence of HIV Infection in France
5.5.84: French Influenza Vaccines, 1998-99
5.5.85: Measles, Mumps and Rubella Immunisations in French Infants
5.5.86: Prevalence of Migraine in France
5.5.87: Incidence of Medicine-Induced Hospitalisation in France
Germany
Market Data
5.5.88: German Pharmacy Sales, 1997
5.5.89: German Pharmacy Sales by Leading Therapeutic Category, 1997
5.5.90: German Market Structure, 1997
5.5.91: Top-Selling Pharmaceutical Products in Germany, 1996
5.5.92: Top Selling Recently-Launched Products in Germany, 1996
5.5.93: German Generic Market, 1996
5.5.94: Ratio of Doctors to Patients in Germany, 1997
5.5.95: German Pharmaceutical Exports, 1997
5.5.96: German Sales of Bioengineered Pharmaceuticals, 1997
5.5.97: Volume of Unused Pharmaceuticals Collected in Hamburg, 1995 - 1997
Industry Data
5.5.98: Top 10 Companies by Pharmaceutical Market Share in Germany, 1998
5.5.99: German Pharmaceutical Companies' Domestic Market Share, 1997
5.5.100: German Pharmacy Data, 1992 - 1998
5.5.101: Direct-to-Pharmacy Sales in Germany, 1997
5.5.102: German Parallel Import Statistics, 1990 - 1997
5.5.103: German Biotechnology Industry, 1995 - 1998
5.5.104: German Biotechnology Industry Data, 1997
5.5.105: Bavarian Pharmaceutical Industry
Regulation
5.5.106: German Krankenkassen Financial Data, 1997
5.5.107: German Krankenkassen Expenditure, 1997
5.5.108: Krankenkassen Pharmaceutical Expenditure, 1997
5.5.109: German Krankenkassen Reimbursement Market, 1997
5.5.110: German Reference Price Market, 1997
5.5.111: Regional Krankenkassen Prescription Costs, 1997
5.5.112: German Expenditure on Special Preparations, 1996
5.5.113: Prescription of Costlier Products in Germany, 1997
5.5.114: German Diabetes Prescription Expenditure, 1996
5.5.115: German Pharmaceutical Budget Ceiling, 1999
5.5.116: German Outpatient Expenditure, 1996
5.5.117: German Vaccine Expenditure, 1997
Therapeutic Data
5.5.118: Prevalence of Osteoporosis in Germany
5.5.119: Prevalence of Lyme Disease in Germany, 1997
Greece
5.5.120: Greek Registration Fees, 1998
5.5.121: Greek Calcitonin Market
Iceland
5.5.122: Liberalisation of Pharmacies in Iceland, 1996 - 1998
Ireland
5.5.123: Investment in the Irish Pharmaceutical Industry
5.5.124: Irish Medicines Board Activities, 1997
5.5.125: Irish Medicines Board Activities, 1996
Italy
Market Data
5.5.126: Italian Pharmaceutical Sales, 1997
5.5.127: Italian Pharmaceutical Retail Sales by Therapeutic Category, 1997
5.5.128: Italian Pharmaceutical Production by Business Segment, 1997
5.5.129: Italian Product Data, 1997
5.5.130: Leading OTC Categories by Expenditure, 1997
5.5.131: Italian Pharmaceutical Expenditure by Drug Class, 1997
5.5.132: Italian Expenditure on Class C Drugs, 1994 - 1997
Industry Data
5.5.133: Italian Pharmaceutical Companies' Turnover, 1997
5.5.134: Italian R&D Expenditure, 1997
5.5.135: Italian Trade Data, 1997
5.5.136: Italian Promotional Expenditure, 1997
5.5.137: Number of Wholesalers and Pharmacies in Italy, 1997
5.5.138: Ratio of Pharmacies to Population, 1995
Regulation
5.5.139: Italian State Drug Expenditure, 1990 - 1998
5.5.140: Pharmaceutical Expenditure in Italy, 1997
5.5.141: Italian Reimbursed Product Price Increases, 1998
5.5.142: Italian Drug Reimbursement, 1998
5.5.143: Italian Pharmaceutical Expenditure Forecast, 1998
5.5.144: Italian Pharmaceutical Budget, 1999 - 2000
5.5.145: Italian Regulatory Activities, 1998
5.5.146: Regulatory Approval Times in Italy, 1998
Therapeutic Data
5.5.147: Number of Terminal Cancer Patients in Italy
5.5.148: Prevalence of Psoriasis in Italy
5.5.149: Prevalence of Sexual Dysfunction in Italy
5.5.150: Prevalence of Asthma in Italy
Portugal
Market Data
5.5.151: Portuguese Pharmaceutical Market, 1997
Regulation
5.5.152: Portuguese National Health Service Expenditure, 1997
5.5.153: Portuguese NHS Pharmaceutical Sales by Product Category, 1997
5.5.154: Portuguese Reimbursable Pharmaceuticals Price Increase, 1998
5.5.155: Portuguese Pharmaceutical Expenditure, 1995-1996
5.5.156: Portuguese Pharmaceutical Product Approvals, 1997
5.5.157: Portuguese Adverse Drug Reaction Reports, 1996 - 1997
The Netherlands
5.5.158: Dutch Regulatory Activities, 1997
Scandinavia
Denmark
5.5.159: Danish Pharmaceutical Market, 1997
5.5.160: Leading Products in Denmark, 1997
5.5.161: Danish Pharmaceutical Sales by Active Ingredient, 1997
5.5.162: Leading Pharmaceutical Companies in Denmark, 1997
5.5.163: Danish Pharmaceutical Reimbursement, 1997
5.5.164: Danish Medicines Agency, 1997
Finland
5.5.165: Pharmaceutical Sales in Finland, 1997
5.5.166: Top Nine Pharmaceuticals in Finland, 1997
5.5.167: Leading Pharmaceutical Companies in Finland by Market Share, 1997
5.5.168: Finnish Medicines Expenditure, 1996
5.5.169: The Mutual Recognition Procedure in Finland, 1997
5.5.170: Measles, Mumps and Rubella Vaccinations in Finland, 1982 - 1996
Norway
5.5.171: Norwegian Pharmaceutical Market, 1997
5.5.172: Top 10 Prescription Products by Value in Norway, 1997
5.5.173: Top 10 Product Sales by Volume in Norway, 1997
5.5.174: Top 10 Best Selling New Products in Norway, 1997
5.5.175: Leading OTCs in Norway, 1997
Sweden
5.5.176: Swedish Pharmaceutical Sales, 1997
5.5.177: Top Ten Pharmaceutical Products in Sweden, 1997
5.5.178: Value of Parallel Imports to the Swedish Market, 1997
5.5.179: Nine Leading Groups in Sweden, 1997
5.5.180: Apoteket's Sales, 1997
5.5.181: Swedish Reference Price Market Value, 1993-1996
5.5.182: Swedish Pharmaceutical Costs, 1998
5.5.183: Effect of Swedish Reference Prices on the Generic Market
5.5.184: Prevalence of Impotence in Sweden
5.5.185: Measles, Mumps & Rubella Vaccination in Sweden
Spain
Market Data
5.5.186: Spanish Pharmaceutical Market Data, 1997
5.5.187: Top 10 Spanish Therapeutic Categories, 1997
5.5.188: Generics in Spain, 1997 - 1998
5.5.189: Spanish OTC Sales, 1997
Industry Data
5.5.190: Spanish Pharmaceutical Industry, 1997
5.5.191: Leading Pharmaceutical Companies in Spain, 1997
5.5.192: Spanish Pharmaceutical R&D Forecast, 1997 - 1998
5.5.193: Spanish Pharmaceutical Trade Balance, 1997
5.5.194: Spanish Hospital Debt to the Pharmaceutical Industry, 1998
5.5.195: Spanish Pharmaceutical Distribution Market, 1997
Regulation
5.5.196: Spanish Government Pharmaceutical Expenditure, 1997
5.5.197: Spanish Pharmaceutical Expenditure Forecast, 1998
5.5.198: Spanish Expenditure on Pharmaceuticals by Region, 1997
5.5.199: Spanish National Healthcare Budget, 1999
5.5.200: Spanish Reference Pricing Forecast, 1999
5.5.201: Spanish Pharmaceutical Production, 1997
5.5.202: Generic Approvals In Spain, 1997
5.5.203: Spanish Delisting of Pharmaceutical Products, 1998
5.5.204: Spanish Patient Co-Payments, 1988 - 1998
Therapeutic Data
5.5.205: Prevalence of Erectile Dysfunction in Spain
Miscellaneous
5.5.206: Spanish Healthcare Computer System
Switzerland
Market Data
5.5.207: Swiss Pharmaceutical Market
5.5.208: Swiss Multisource Market, 1997
5.5.209: Swiss Pharmaceutical Data, 1997
Regulation
5.5.210: Drug Approval Times in Switzerland, 1997
5.5.211: Swiss Regulatory Activities, 1997
5.5.212: Price Reduction of Reimbursed Pharmaceuticals in Switzerland, 1999
United Kingdom
Industry Data
5.5.213: UK Pharmaceutical Industry Data
5.5.214: Value of the UK Pharmaceutical Industry, 1997
5.5.215: Capital Investment by the UK Pharmaceutical Industry, 1997
5.5.216: Government Regional Assistance to UK Inward Investors, 1995 - 1998
5.5.217: Leading UK Pharma R&D Spenders, 1997
5.5.218: UK Pharmaceutical Research & Development Expenditure, 1997
5.5.219: UK Biotechnology Industry Data, 1997 - 1998
5.5.220: UK Expenditure on Science and Technology, 1996 - 1999
5.5.221: Intellectual Property Protection in the UK, 1996
5.5.222: Top Ten UK Companies by Salesforce Size, 1997/98
5.5.223: Number of Sales Representatives Visiting UK GPs in 1997
5.5.224: Norton, the Leading Generics Company in the UK, 1997
NHS Data
5.5.225: NHS Pharmaceutical Expenditure, 1992-1997
5.5.226: UK Government Annual Expenditure on Sickness Benefit
5.5.227: UK Government Increase in NHS Expenditure, 1998
5.5.228: UK Hospital Pharmaceutical Expenditure in 1996/1997
5.5.229: Annual NHS Expenditure on Treatment of Major Diseases
5.5.230: Cost of Chronic Obstructive Pulmonary Disease to the NHS
5.5.231: Annual Cost of HIV and AIDS Treatment to the NHS
5.5.232: Net Ingredient Cost of Anti-asthmatics in Scotland, 1993 - 1998
5.5.233: Cost of Gastrointestinal Prescriptions to the NHS, 1997
5.5.234: Annual NHS Expenditure on Chemotherapy
5.5.235: Cost of Hormone Replacement Therapy to the UK NHS
5.5.236: Annual Cost of Waste Medicines in England
5.5.237: Cost of "Unsuitable" Products to the NHS
5.5.238: Cost of Co-proxamol to the NHS, 1995 - 1997
5.5.239: Net Ingredient Cost of Parallel Imports to the NHS, 1997/98
5.5.240: Cost of Pharmaceuticals to the UK Family Health Service, 1997
5.5.241: UK Health Authorities' and Hospital Trust's Financial Data, 1996 - 1998
5.5.242: Annual Cost of Prescription Fraud to the NHS
5.5.243: Annual Cost of Fraud to the NHS
5.5.244: Cost of Fraud to the UK NHS Primary Care Sector, 1998
5.5.245: Cost of Clinical Negligence to the NHS, 1996-97
5.5.246: UK Prescription Data in England, 1997
5.5.247: UK Prescription Charge Data, 1996
5.5.248: Highest and Lowest Medicine Costs in the UK, 1997
5.5.249: Variations in UK Medical Treatment Costs
5.5.250: Average Total Cost per Prescription in England, 1997/98
5.5.251: Variations in Prescribing in England
5.5.252: Number and Net Ingredient Cost of Prescription Items in England, 1997
5.5.253: Geographical Variations in Net Ingredient Cost in the UK
5.5.254: Net Ingredient Cost of NHS Prescriptions, 1993 - 1997
5.5.255: Dispensing General Practitioners in England, 1987 - 1997
5.5.256: Generic Prescriptions in the UK's Leading Therapeutic Categories, 1997
5.5.257: Prescription Fee Payments in England, 1997/98
5.5.258: Number of Community Pharmacists in England, 1997/98
5.5.259: Repeat Prescribing in the UK, 1996
5.5.260: UK Prescription Charge Income, 1995-1997
5.5.261: Cost of Pack Dispensing in the UK, 1998
5.5.262: UK Government Levies on the Pharmaceutical Industry, 1993-1997
5.5.263: UK Asthma Prescription Costs, 1994 - 1996
5.5.264: Antibacterial Prescription Items in England
5.5.265: UK Diabetes Prescription Expenditure, 1996
5.5.266: UK Government Target for Public Health, 1998-2010
5.5.267: Annual Growth of NHS Waiting Lists and Emergency Hospital Admissions
5.5.268: Chronic Disease Management by UK General Practitioners, 1997
5.5.269: Allocated Revenue for UK Health Authorities, 1999 - 2000
5.5.270: Hospitalisations Due to Adverse Drug Reactions in the UK, 1994
5.5.271: Annual Cost of Resale Price Maintenance on OTC Medicines
5.5.272: UK Medicine Exports, 1997
5.5.273: UK Pharmaceutical Trade with Egypt, 1997
Regulation
5.5.274: UK Suspected Adverse Drug Reaction Reports, 1993 - 1997
5.5.275: UK Good Manufacturing Practice Deficiencies, 1996/97
5.5.276: UK Medicines Control Agency Activities, 1997-98
5.5.277: UK Prescription Pricing Authority Activities, 1997/98
5.5.278: Parallel Import Applications in the UK, 1997
5.5.279: UK PMCPA Code Complaints, 1997
5.5.280: Pharmaceutical Price Regulation Scheme Payment to the NHS, 1994
5.5.281: UK "One Month" Pack Size
Therapeutic Data
Alimentary/Metabolic
5.5.282: UK Obesity Market
5.5.283: Prevalence of Irritable Bowel Syndrome in the UK
5.5.284: UK Incidence of Nephrotic Cystinosis in Children
5.5.285: UK Consumption of Albumin
Cancer
5.5.286: UK Cancer Survival Rates, 1981 - 1989
5.5.287: UK Breast Cancer Mortality, 1985 - 1995
5.5.288: Incidence of Ovarian Cancer in the UK
Genitourinary
5.5.289: Prevalence of Incontinence in the UK
5.5.290: UK Incontinence Drug Market
5.5.291: Number of Abortions in England and Wales, 1996
5.5.292: Incidence of Chlamydia Trachomatis in the UK, 1996
Hormonal
5.5.293: UK Hormone Replacement Therapy Market
Immunological
5.5.294: UK HIV/AIDS Budget, 1998-1999
Infectious Diseases
5.5.295: Tuberculosis Cases in the UK, 1987-1997
5.5.296: UK Antibiotics Market
5.5.297: UK Influenza Immunisations, 1997
5.5.298: Influenza Vaccine ADRs in the UK, 1988-1997
5.5.299: Number of Measles, Mumps and Rubella Vaccinations in the UK
Musculoskeletal
5.5.300: Incidence of Osteoporosis in Northern Irish Hospitals, 1996-1997
Neurological
5.5.301: Incidence and Cost of Parkinson's Disease in the UK
5.5.302: Incidence of Stroke and Mini-Stroke in England
5.5.303: Incidence of Narcolepsy in the UK
5.5.304: UK Incidence of New-Variant Creutzfeldt-Jakob Disease, 1995 - 1998
5.5.305: Number of Smokers in the UK
5.5.306: Prevalence of Cannabis Use in UK Multiple Sclerosis Patients
5.5.307: Market for Controlled-Release Carbamazepine Tablets
5.5.308: UK NHS Antidepressant Expenditure, 1997
5.5.309: Number of Prescriptions for Antidepressants Issued in England, 1996
5.5.310: Anxiolytic Link to Road Traffic Accidents
Respiratory
5.5.311: Prevalence of Asthma in the UK
5.5.312: UK Incidence of Chronic Obstructive Pulmonary Disease
Miscellaneous
5.5.313: Animal Research Data, 1995-1999
5.5.314: Reduction in Hospital-Stay in the UK
5.5.315: UK Market for "Homecare" Products
5.6: FAR EAST
5.6.1: Asian Self-Medication Market, 1997
5.6.2: Southeast Asian OTC Sales by Country, 1997
5.6.3: Southeast Asian OTC Sales by Sector, 1997
5.6.4: Incidence of Impotence in Asia
China
Market Data
5.6.5: Chinese Pharmaceutical Market, 1997
5.6.6: Chinese OTC Market, 1993 - 1997
Industry Data
5.6.7: China's Pharmaceutical Output, 1997
5.6.8: Chinese Biotechnology Industry, 1998
Regulation
5.6.9: Price Control Regulations in China, 1997 - 1998
Therapeutic Data
5.6.10: Cases of Diabetes in China
5.6.11: Prevalence of Hepatitis B in China
5.6.12: Chinese Incidence of Chronic Renal Failure
5.6.13: Prevalence of HIV/AIDS in China
5.6.14: Chinese Asthma Market, 1997
5.6.15: Forecast of Mortality due to Smoking-Related Diseases in China, 2020
Hong Kong
5.6.16: Hospital Authority Expenditure in Hong Kong
Indonesia
5.6.17: Leading Foreign Pharmaceutical Companies in Indonesia, 1997/98
5.6.18: Value of Indian Exports to Indonesia
Japan
Market Data
5.6.19: Japanese Pharmaceutical Market Forecast, 2001
5.6.20: Japanese OTC Market, 1997/98
5.6.21: Japanese Expenditure on OTCs, 1997
5.6.22: Japanese Monthly Expenditure on OTC Medications
5.6.23: Top Five Therapeutic Categories of Prescription Pharmaceuticals in Japan, 1996
5.6.24: Globally Launched Drugs in Japan
5.6.25: OTC H2-antagonists Market in Japan
5.6.26: Number of Japanese Pharmacies and Drugstores, 1997
5.6.27: Sales Forecast for the Top Ten Japanese-Originated Blockbuster Drugs
5.6.28: Top Five Markets for Pharmaceutical Imports and Exports in Japan, 1996
5.6.29: Entry Barriers to the Japanese Pharmaceutical Market
5.6.30: Japanese Generics Market Value, 1998
Industry Data
5.6.31: Japanese Major Companies' Financial Results, 1997/98
5.6.32: Top 10 Japanese Companies' Sales Forecast, 1998/99
5.6.33: Leading Domestic Product Sales of the Major Japanese Companies, 1997/98
5.6.34: OTC Sales by Major Japanese Companies, 1997/98
5.6.35: Leading Japanese Pharmaceutical Groups by Market Capitalisation, 1997
5.6.36: Japanese Pharmaceutical Production, 1996
5.6.37: Japanese Pharmaceutical Production Forecast to 2006
5.6.38: Globalisation of Japanese Pharmaceutical Companies, 1996-1998
5.6.39: Japanese Pharmaceutical Companies' Operations in Europe
5.6.40: Japanese Pharmaceutical Industry Employment Figures, 1995
Regulation
5.6.41: Japanese Reimbursement Price Revision, 1998
5.6.42: Japanese Reimbursement Price Cuts on Pharmaceutical Products, 1998
5.6.43: Special Price Cuts in the Japanese Reimbursement Price Revision, 1998
5.6.44: Japanese Health Insurance Expenditure, 1997/98
5.6.45: Forecast for Japanese National Healthcare Expenditure, 1998 - 1999
5.6.46: Japanese Medical Expenditure, 1996/97
5.6.47: Japanese Pharmaceutical Expenditure, 1996
5.6.48: Japanese Generic Listing, 1998
5.6.49: Japanese Pharmaceutical Patents, 1996
5.6.50: Japanese Ministry of Health and Welfare Financial Data, 1996
5.6.51: Drug Approval Times in Japan
5.6.52: Number of Orphan Products in Japan, 1998
5.6.53: Japanese Pharmaceutical Costs for Outpatients Over 70
Therapeutic Data
5.6.54: Japanese Market for Anti-Obesity Products
5.6.55: Potential Japanese Market for Low-Dose Oral Contraceptives
5.6.56: Incidence of Dementia in Japan
5.6.57: Prevalence of Amyotrophic Lateral Sclerosis in Japan
5.6.58: Prevalence of Multiple Sclerosis in Japan
5.6.59: Japanese Osteoporosis Market
5.6.60: Japanese Rheumatic Market
5.6.61: Japanese Glaucoma Market
Laos
5.6.62: Incidence of Opisthorchiasis in Laos
Malaysia
5.6.63: Malaysian Pharmaceutical Market
5.6.64: Malaysian Government Healthcare Expenditure, 1998
5.6.65: Malaysian ADR Reports, 1997
5.6.66: Incidence of Erectile Dysfunction in Malaysia
The Philippines
5.6.67: Generic Share of the Philippines Prescription Market
5.6.68: Incidence of HIV in the Philippines
5.6.69: Incidence of Tuberculosis in the Philippines
South Korea
Market Data
5.6.70: South Korean Pharmaceutical Market, 1996 - 1998
5.6.71: South Korean Medical Expenditure, 1995
Industry Data
5.6.72: Sales of Leading Foreign Affiliated Companies in South Korea, 1997
5.6.73: Leading South Korean Pharmaceutical Companies' R&D Expenditure, 1997
5.6.74: Delays in Payments for Pharmaceuticals in South Korea
Regulation
5.6.75: South Korean Pharmaceutical Reimbursement Price Cuts, 1997
5.6.76: South Korean Reimbursement Price Increases, 1998
5.6.77: South Korean Pharmaceutical Classification, 1998
5.6.78: South Korean Pharmaceutical Output, 1997
5.6.79: Adverse Drug Reactions in South Korean Clinical Trials, 1997 - 1998
Therapeutic Data
5.6.80: South Korean Market for Anti-ulcer Products, 1997 - 1998
5.6.81: South Korean Quinolone Market, 1997
5.6.82: South Korean Antifungal Market, 1997
5.6.83: South Korean Anti-asthmatic Market, 1997
Taiwan
5.6.84: Taiwanese Pharmaceutical Expenditure
5.6.85: Drug Approval Times in Taiwan
5.6.86: Taiwanese Market for Alpha-Interferon, 1996
Thailand
5.6.87: Thai Pharmaceutical Market, 1997
5.6.88: Cases of Impotence in Thailand
Vietnam
5.6.89: Imported Drugs in Vietnam, 1996 - 1998
5.6.90: Vietnamese Pharmaceutical Industry, 1998
5.7: NEAR/MIDDLE EAST
India
Market Data
5.7.1: Indian Pharmaceutical Market, 1998 - 2010
5.7.2: Top 10 Therapeutic Categories in India by Sales, 1997/98
5.7.3: Indian Pharmaceutical Production and Exports, 1993 - 1998
5.7.4: Indian Pharmaceutical Production and Export Targets, 1997 - 2002
5.7.5: Indian Biotechnology Exports
5.7.6: Indian Imports, 1994 - 1997
5.7.7: Annual Turnover of Price-Controlled Drugs in India
Industry Data
5.7.8: Indian Pharmaceutical Industry Data, 1997/98
5.7.9: Leading Pharmaceutical Companies in India in 1997/98
5.7.10: Foreign Investment in the Indian Pharmaceutical Industry, 1991 - 1997
5.7.11: Pharmaceutical Patent Applications in India, 1997
5.7.12: Incidence of Leptospirosis in India, 1997
Iran
5.7.13: Iranian Prescription Costs, 1998
Israel
5.7.14: Israeli Annual Expenditure on Imported Drugs
Jordan
5.7.15: Jordanian Pharmaceutical Exports
5.7.16: The Annual Cost of Jordanian Pharmaceutical Piracy
Lebanon
5.7.17: Lebanese Pharmaceutical Consumption, 1997
Pakistan
5.7.18: Pakistani Pharmaceutical Market, 1997
5.7.19: Pakistan's National Health Policy, 1998-2003
5.7.20: Drug Approvals in Pakistan
5.7.21: Annual Incidence of Haemophilus influenzae B in Pakistan
Turkey
5.7.22: Turkish Pharmaceutical Market, 1997
5.7.23: Leading Pharmaceutical Companies in Turkey, 1997
5.7.24: Leading Therapeutic Categories in Turkey, 1997
5.7.25: Turkish Pharmaceutical Trade Data, 1997
5.8: RUSSIA AND THE FORMER SOVIET UNION
Baltic States
5.8.1: Clinical Trial Procedure in the Baltic States
Estonia
5.8.2: Estonian Pharmaceutical Market, 1997
5.8.3: Estonian Pharmaceutical Sales by the Multinational Pharmaceutical Association, 1997
5.8.4: Tallin, Estonia's Largest Pharmaceutical Company
Russia
Market Data
5.8.5: Russian Pharmaceutical Market, 1997
5.8.6: Russian Pharmaceutical Market Forecast
5.8.7: Russian Direct Sales Pharmacy Market, 1997
5.8.8: Russian OTC Market, 1997
5.8.9: Private Healthcare Expenditure in Russia
5.8.10: Russian Pharmaceutical Market, 1996
Industry Data
5.8.11: The Pharmaceutical Industry in Russia
5.8.12: Leading Russian Pharmaceutical Companies, 1997
5.8.13: Russian Pharmaceutical Data, 1997
5.8.14: Russian Pharmaceutical Production, 1997
5.8.15: Russian Pharmaceutical Imports by Area, 1997
5.8.16: Top 10 Importers in Russia, 1997
5.8.17: Fastest Growing Importers in Russia, 1997
Regulation
5.8.18: Clinical Trial Practice in Russia
Therapeutic Data
5.8.19: Russian Antidiabetic Market, 1996
5.8.20: Incidence of Erectile Dysfunction in the Over 35s in Russia
5.8.21: Cost of Tuberculosis Control in Russia
Ukraine
Market Data
5.8.22: Ukraine Pharmaceutical Market Data

Industry Data
5.8.23: Fastest Growing Domestic Pharmaceutical Companies in Ukraine, 1997
5.8.24: Pharmaceutical Exports to Ukraine, 1997
5.8.25: Top Ten Pharmaceutical Exporters to Ukraine 1996-1997
5.8.26: Ukrainian Pharmaceutical Imports by Therapeutic Category, 1997
Uzbekistan
5.8.27: Uzbekistan Pharmaceutical Supply, 1997
5.9: REST OF THE WORLD
The Caribbean
5.9.1: Prevalence of Type 2 Diabetes in the Caribbean
Developing Countries
5.9.2: Effect of Debt Relief on Healthcare in Developing Countries
Western Pacific
5.9.3: Incidence of Dengue in Fiji, 1997-1998
5.9.4: Incidence of HIV/AIDS and Sexually Transmitted Diseases in the Western Pacific
5.9.5: Incidence of Polio in the Western Pacific Region, 1997
OECD Countries
5.9.6: Premature Mortality Rates, 1960 - 1998
5.9.7: Health Expenditure in OECD Countries, 1995 - 1997

Publications: January 1999
Ref: BS992E
Pages: 500+
Price: £395/$830/¥95,000

• Order this report.
• Request a catalogue.

© PJB Publications Ltd. 2000 All rights reserved.